2023-507445-28-00
CTIS ↗
A study to compare two different aramchol formulations in healthy volunteers.
Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
pharma · Fatty Liver · Inflammatory Disease · GLMD
Galmed Pharmaceuticals
Galmed Pharmaceuticals trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA HQ
2000 Founded
10 Employees
Public company Type
GLMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA
- Founded
- 2000
- Employees
- 10
- Programs
- 13
- Drugs
- 5
- Patents
- 11
Galmed Pharmaceuticals clinical trials
Registry index of 17 ClinicalTrials.gov studies linked to Galmed Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.
Galmed Pharmaceuticals trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Galmed Pharmaceuticals.
-
A study to compare two different aramchol formulations in healthy volunteers. — Phase 1
Clinical update -
mFOLFOX6 + BIBF 1120 — Phase 2
Clinical update -
Aramchol — Phase 2
Clinical update -
Aramchol free acid tablet 600mg, single dose — Phase 1
Clinical update -
Aramchol free acid — Phase 3
Clinical update -
Aramchol — Phase 2
Clinical update -
Aramchol — Phase 2
Clinical update -
Aramchol meglumine — Phase 2
Clinical update